Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gentbrugge – page 48

1 787 clinical trials in Gentbrugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gentbrugge at a glance
1 787
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 787 trials in Gentbrugge

Open in trial search

Study on Colchicine for Patients with Coronary Artery Disease After Percutaneous Coronary Intervention

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Az St-Jan Brugge-Oostende A.V.

Prostate cancer

Recruiting

Study on High-Risk Prostate Cancer Treatment Using Darolutamide, Relugolix, and Drug Combination for Eligible Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Ziekenhuis Aan De Stroom

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obrixtamig
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Ovarian cancer

Recruiting

Study of Abemaciclib and Letrozole for Patients with Estrogen Receptor Positive Low-Grade Serous Ovarian Cancer and Adult-Type Granulosa Cell Tumor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:UZ Leuven

Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Long-term Safety Study of Ciltacabtagene Autoleucel for Patients with Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ciltacabtagene Autoleucel
  • Sponsor:Janssen Cilag International

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Tividenofusp alfa
  • Sponsor:Denali Therapeutics Inc.

Study on Conditioning Treatments with Busulfan, Clofarabine, and Fludarabine for Children with Acute Myeloid Leukemia Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:Vastra Gotalandsregionen

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gentbrugge

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) medication management in primary care settings. This research examines optimal strategies for reducing long-term PPI use in patients without clear medical necessity.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn Management

The study compares various deprescribing approaches, including on-demand PPI use and alternative treatments with alginate formulations, aiming to establish more effective medication management protocols for patients with chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.